Year: 2020
Type: review
Abstract: While the development of positron emission tomography (PET) radiopharmaceuticals closely follows that of traditional drug development, there are several key considerations in the chemical and radiochemical synthesis, preclinical assessment, and clinical translation of PET radiotracers. As such, we outline the fundamentals of radiotracer design, with respect to the selection of an appropriate pharmacophore. These concepts will be reinforced by exemplary cases of PET radiotracer development, both with respect to their preclinical and clinical evaluation. We also provide a guideline for the proper selection of a radionuclide and the appropriate labeling strategy to access a tracer with optimal imaging qualities. Finally, we summarize the methodology of their evaluation in in vitro and animal models and the road to clinical translation. This review is intended to be a primer for newcomers to the field and give insight into the workflow of developing radiopharmaceuticals.
Source: Cancers
Authors: Joseph Lau(Conceptualization, Writing – original draft, Writing – review & editing), Etienne Rousseau(Writing – original draft, Writing – review & editing), Daniel Kwon(Writing – original draft), Kuo-Shyan Lin(Writing – review & editing), François Bénard(Supervision, Writing – review & editing), Xiaoyuan Chen(Conceptualization, Funding acquisition, Supervision, Writing – review & editing)
Language: English
Subfield: Radiology, Nuclear Medicine and Imaging
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,324
OpenAlex ID: W3027879015
